Stocklytics Platform
Asset logo for symbol NAMSW
NewAmsterdam Pharma Company N.V.
NAMSW1
$8.70arrow_drop_down2.46%-$0.22
Asset logo for symbol NAMSW
NAMSW1

$8.70

arrow_drop_down2.46%

Performance History

Chart placeholder
Key Stats
Open$8.92
Prev. Close$8.92
EPS-
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap-
PE Ratio-
LOWHIGH
Day Range8.60
8.92
52 Week Range0.99
14.67
Ratios
Revenue-
EPS-

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Correlated Companies

Asset logo for symbol CAT
Caterpillar
CAT78
Price$350.48
Perf. (24h)
arrow_drop_up1.79%$6.18
Market Cap$171.40B
HTFC
Horizon Technology Finance Corporation 6.25% Notes due 2027
HTFC26
Price$23.75
Perf. (24h)
arrow_drop_down0.34%-$0.08
Market Cap$36.81B
OXLC
Oxford Lane Capital Corp. - 5.00% Notes due 2027
OXLCZ35
Price$23.39
Perf. (24h)
arrow_drop_up0.30%$0.07
Market Cap$36.79B
RWAY
Runway Growth Finance Corp. - 7.50% Notes due 2027
RWAYL35
Price$25.02
Perf. (24h)
arrow_drop_up0.08%$0.02
Market Cap$12.75B

About NewAmsterdam Pharma Company N.V. (NAMSW)

NewAmsterdam Pharma Company N.V. (NAMSW) is a pharmaceutical company that focuses on the development and commercialization of innovative drugs. The company is known for its expertise in the field of drug discovery and has a strong pipeline of potential blockbuster drugs. With a market cap of $X, the company is well-positioned to capitalize on the growing demand for effective and safe medications.
One of the key strengths of NewAmsterdam Pharma Company N.V. is its smart analysis capabilities. The company leverages advanced analytics and machine learning algorithms to identify promising drug candidates and predict their market potential. This enables NewAmsterdam Pharma Company N.V. to make data-driven decisions and prioritize its R&D efforts.
Websitecall_made
Sector
Industry
CEO
Headquarters
Employees
0
Exchange
NASDAQ
add NewAmsterdam Pharma Company N.V. to watchlist

Keep an eye on NewAmsterdam Pharma Company N.V.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is NewAmsterdam Pharma Company N.V.'s (NAMSW) price per share?
The current price per share for NewAmsterdam Pharma Company N.V. (NAMSW) is $8.7. The stock has seen a price change of -$0.22 recently, indicating a -2.47% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for NewAmsterdam Pharma Company N.V. (NAMSW)?
For NewAmsterdam Pharma Company N.V. (NAMSW), the 52-week high is $14.67, which is 68.62% from the current price. The 52-week low is $0.99, the current price is 778.79% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is NewAmsterdam Pharma Company N.V. (NAMSW) a growth stock?
NewAmsterdam Pharma Company N.V. (NAMSW) has shown an average price growth of 0.41% over the past three years. It has received a score of 0 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying NewAmsterdam Pharma Company N.V. as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is NewAmsterdam Pharma Company N.V. (NAMSW) stock price performance year to date (YTD)?
As of the latest data, NewAmsterdam Pharma Company N.V. (NAMSW) has a year-to-date price change of 185.25%. Over the past month, the stock has experienced a price change of -8.42%. Over the last three months, the change has been -10.59%. Over the past six months, the figure is -30.4%.
help
Is NewAmsterdam Pharma Company N.V. (NAMSW) a profitable company?
NewAmsterdam Pharma Company N.V. (NAMSW) has a net income of -$176.94M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -3.96K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $14.05M. Operating income is noted at -$182.97M. Furthermore, the EBITDA is -$198.54M.
help
What is the market capitalization of NewAmsterdam Pharma Company N.V. (NAMSW)?
NewAmsterdam Pharma Company N.V. (NAMSW) has a market capitalization of . The average daily trading volume is 1.86K, indicating the stock's liquidity and investor engagement.

News

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
COMPANY ANNOUNCEMENT
6/7/2024

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HEALTH
INSIDER'S BUY/SELL
MANAGEMENT STATEMENTS
5/3/2024

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
CLINICAL STUDY
4/9/2024

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
DIRECTORS AND OFFICERS
4/1/2024

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
INITIAL PUBLIC OFFERINGS
MAJOR SHAREHOLDER ANNOUNCEMENTS
MANAGEMENT STATEMENTS
2/14/2024

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
FINANCING AGREEMENTS
2/13/2024

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level